Abbasinejad, MD , evaluates each patients medical history, current weight, previous weight loss efforts, medications, lifestyle, and overall health goals before determining whether Contrave may be appropriate
The peptide does not suddenly become useless on day 29
weight loss), and minimization of side effects
Key findings include: Diabetic patients on Semaglutide medications are over four times more likely to develop NAION
This dual-pathway approach reaches people who don't respond adequately to semaglutide alone because it triggers appetite suppression through two independent biological mechanisms
Both states share one non-negotiable rule: a good-faith medical exam by a licensed provider is required before any prescription